Open menu

Nanotechnology Business News

The latest product and company news

RSS Subscribe to our Nanotechnology Business News feed

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

Calando Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its investigational new drug application for lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase formulated with Calando?s proprietary RONDEL polymer delivery system.

Posted: Apr 22nd, 2008

Read more

Renesas Collaborates With IMEC on Reconfigurable RF Transceivers

Renesas Technology Corp., one of the world's leading semiconductor system solutions providers for mobile, automotive and PC/AV (Audio Visual) markets, has entered into a strategic research collaboration with IMEC, Europe's leading independent research center in the field of nanoelectronics, to perform research on 45nm RF transceivers targeting Gbit/s cognitive radios.

Posted: Apr 21st, 2008

Read more

As the Disposable Battery Market Dims, Rechargeables Charge Ahead

As innovation in the battery market continues to meet consumer and product demands, SBI's new report, U.S. Batteries Market, estimates a compound annual growth rate of 5% for rechargeable batteries from 2002 to 2007, compared with flat growth for disposables. SBI expects the overall battery market to dip in 2008, followed by steady growth in spite of challenging economic times, topping $9 billion by 2012.

Posted: Apr 18th, 2008

Read more

Neuftec Patent Validity Confirmed in Re-Examination Proceedings Initiated by Oxonica PLC

Neuftec Limited, the proprietor of the original nano-particulate cerium Oxide fuel catalyst technology, today announced that IP Australia, the Australian government agency responsible for administering patents, trade marks and designs, has recently confirmed the validity of Neuftec's Australian Patent No. 2001267700 in Re-examination proceedings initiated by Oxonica PLC.

Posted: Apr 18th, 2008

Read more